Prospective, case series.Setting
A university pediatric intensive care and pediatric subacute units.Patients
Nineteen infants and children who received CNA for at least 24 hours.Interventions
Creatinine phosphokinase (CK) was measured at the time of admission and then at 12, 24, 48, and 72 hours while the patient received CNA. Isoenzyme CK-MB fractions were measured if CK concentration was >=250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy.Conclusions
Continuous albuterol therapy appears to be safe in our patient population as there was no significant evidence of cardiotoxicity. The significance of the transient elevation of CK-MB without other evidence of cardiotoxicity remains to be determined. Pediatrics 1993;92:666-669; talbuterol, continuous nebulization, bronchospasm, cardiotoxicity, myocardial ischemia, creatinine phosphokinase, arrhythmia.